Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 2, 2005, Pages 186-194

  Nakata, Tomoaki ^a   Wakabayashi, Takeru ^a   Kyuma, Michifumi ^a   Takahashi, Toru ^a   Tsuchihashi, Kazufumi ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autonomic nervous system; Drug treatment; Heart failure; Prognosis; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IMIDAPRIL; LOSARTAN; METOPROLOL; NITRATE; TEMOCAPRIL; VALSARTAN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART; HEART DEATH; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MORTALITY; MULTIVARIATE ANALYSIS; PREVALENCE; PROGNOSIS; QUANTITATIVE ANALYSIS; RISK REDUCTION; SIDE EFFECT;

3-IODOBENZYLGUANIDINE; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; DRUG COMBINATIONS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 13844289178     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1624-8     Document Type: Article

References (26)

1. Zipes DP. Sympathetic stimulation and arrhythmias. N Engl J Med 1991;325:656-7.
2. Kaye D, Lefkovits J, Jennings G, et al. Adverse consequence of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.
3. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
4. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by metaiodobenzylguanidine in patients with failing and non-failing hearts. J Nucl Cardiol 1998;5:579-90.
5. Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.
6. Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.
7. Pritchett AM, Redfield MM. Beta-blockers: new standard therapy for heart failure. Mayo Clin Proc 2002;77:839-45.
8. Hunt HA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
9. Pitt B, Poole-Wilson PA, Sega R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
10. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
11. Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduced cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-9.
12. 123I-MIBG in the failing human heart. J Nucl Med 1999;40:224-31.
13. Sakata K, Shirotani M, Yoshida H, et al. Physiological fluctuation of the human left ventricle sympathetic nervous system assessed by iodine-123-MIBG. J Nucl Med 1998;39:1667-71.
14. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
15. Nakata T, Wakabayashi T, Kyuma M, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail 2003;9:113-21.
16. Inoue H, Zipes DP. Result of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation 1987;75:877-87.
17. Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996;27:1053-60.
18. Mitrani RD, Klein LS, Miles WM, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 1993;22:1344-53.
19. Nakata T, Nagao K, Tsuchihashi K, et al. Regional cardiac sympathetic nerve dysfunction and the diagnostic efficacy of metaiodobenzylguanidine tomography in stable coronary artery disease. Am J Cardiol 1996;78:292-7.
20. McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 metaiodobenzylguanidine tomographic imaging after myocardial infarction. Am J Cardiol 1991;67:236-42.
21. Tobes MC, Jaques S, Wieland DM, et al. Effect of uptake-1 inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985;26:897-907.
22. Miyazaki T, Zipes DP. Presynaptic modulation of efferent sympathetic and vagal neurotransmission in canine heart by hypoxia, high K+, low pH, and adenosine. Possible relevance to ischemia-induced denervation. Circ Res 1990;66:289-301.
23. Rabinovitch MA, Rose CP, Schwab AJ, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
24. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667-76.
25. 123I- metaiodobenzylguanidine (MIBG) imaging and heart rate variability analysis to predict the need for implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31.
26. Nagahara D, Nakata T, Uno K, et al. Cardiac metaiodobenzylguanidine activity in combination with cardiac function or plasma brain natriuretic level can predict the need for an implantable cardioverter defibrillator. Circulation 2003;108(Suppl): IV-544 [Abstract].